JP6446040B2 - Ｋｉｔに関連する疾患を治療するために有用な組成物 - Google Patents

Ｋｉｔに関連する疾患を治療するために有用な組成物 Download PDF

Info

Publication number
JP6446040B2
JP6446040B2 JP2016523939A JP2016523939A JP6446040B2 JP 6446040 B2 JP6446040 B2 JP 6446040B2 JP 2016523939 A JP2016523939 A JP 2016523939A JP 2016523939 A JP2016523939 A JP 2016523939A JP 6446040 B2 JP6446040 B2 JP 6446040B2
Authority
JP
Japan
Prior art keywords
monocyclic
alkyl
bicyclic
mmol
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016523939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538257A5 (OSRAM
JP2016538257A (ja
Inventor
ブライアン エル． ホドゥス，
ブライアン エル． ホドゥス，
ジョセフ エル． キム，
ジョセフ エル． キム，
ケビン ジェイ． ウィルソン，
ケビン ジェイ． ウィルソン，
ダグラス ウィルソン，
ダグラス ウィルソン，
ユリアン ザン，
ユリアン ザン，
Original Assignee
ブループリント メディシンズ コーポレイション
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション, ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2016538257A publication Critical patent/JP2016538257A/ja
Publication of JP2016538257A5 publication Critical patent/JP2016538257A5/ja
Application granted granted Critical
Publication of JP6446040B2 publication Critical patent/JP6446040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2016523939A 2013-10-17 2014-10-15 Ｋｉｔに関連する疾患を治療するために有用な組成物 Active JP6446040B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361892086P 2013-10-17 2013-10-17
US61/892,086 2013-10-17
US201461931204P 2014-01-24 2014-01-24
US61/931,204 2014-01-24
US201461975229P 2014-04-04 2014-04-04
US61/975,229 2014-04-04
PCT/US2014/060746 WO2015057873A1 (en) 2013-10-17 2014-10-15 Compositions useful for treating disorders related to kit

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018224481A Division JP6782756B2 (ja) 2013-10-17 2018-11-30 Ｋｉｔに関連する疾患を治療するために有用な化合物の製法と中間体化合物

Publications (3)

Publication Number Publication Date
JP2016538257A JP2016538257A (ja) 2016-12-08
JP2016538257A5 JP2016538257A5 (OSRAM) 2017-11-24
JP6446040B2 true JP6446040B2 (ja) 2018-12-26

Family

ID=51904226

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016523939A Active JP6446040B2 (ja) 2013-10-17 2014-10-15 Ｋｉｔに関連する疾患を治療するために有用な組成物
JP2018224481A Active JP6782756B2 (ja) 2013-10-17 2018-11-30 Ｋｉｔに関連する疾患を治療するために有用な化合物の製法と中間体化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018224481A Active JP6782756B2 (ja) 2013-10-17 2018-11-30 Ｋｉｔに関連する疾患を治療するために有用な化合物の製法と中間体化合物

Country Status (30)

Country Link
US (7) US9200002B2 (OSRAM)
EP (2) EP3409674B1 (OSRAM)
JP (2) JP6446040B2 (OSRAM)
KR (1) KR102378689B1 (OSRAM)
CN (2) CN110003217B (OSRAM)
AU (1) AU2014337314B2 (OSRAM)
BR (1) BR112016008541B1 (OSRAM)
CA (1) CA2926999C (OSRAM)
CY (2) CY1121182T1 (OSRAM)
DK (1) DK3057969T3 (OSRAM)
ES (2) ES2923888T3 (OSRAM)
HR (1) HRP20181388T1 (OSRAM)
HU (3) HUE059041T2 (OSRAM)
IL (1) IL244677B (OSRAM)
LT (2) LT3057969T (OSRAM)
MX (1) MX365614B (OSRAM)
NL (1) NL301094I2 (OSRAM)
NO (1) NO2021012I1 (OSRAM)
PH (1) PH12016500611A1 (OSRAM)
PL (2) PL3409674T3 (OSRAM)
PT (2) PT3409674T (OSRAM)
RS (1) RS57542B1 (OSRAM)
RU (1) RU2706235C2 (OSRAM)
SG (1) SG11201602937UA (OSRAM)
SI (1) SI3057969T1 (OSRAM)
SM (1) SMT201800448T1 (OSRAM)
TW (1) TWI683814B (OSRAM)
UY (1) UY35787A (OSRAM)
WO (1) WO2015057873A1 (OSRAM)
ZA (1) ZA201601970B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019048878A (ja) * 2013-10-17 2019-03-28 ブループリント メディシンズ コーポレイション Ｋｉｔに関連する疾患を治療するために有用な組成物
US11964980B2 (en) 2019-04-12 2024-04-23 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
UA120248C2 (uk) 2013-03-15 2019-11-11 Селджен Кар Ллс Гетероарильні сполуки та їх застосування
US9663524B2 (en) 2013-03-15 2017-05-30 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
FR3008779B1 (fr) 2013-07-19 2018-01-26 Areva Np Barre antivibratoire pour faisceau de tubes d'un generateur de vapeur
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
CN106231901A (zh) 2014-04-15 2016-12-14 美国陶氏益农公司 作为杀真菌剂的金属酶抑制剂化合物
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
KR20180048635A (ko) 2015-07-24 2018-05-10 블루프린트 메디신즈 코포레이션 Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
CA3005741A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
CN109414442B (zh) 2016-04-04 2024-03-29 洛克索肿瘤学股份有限公司 一种化合物的液体制剂
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP4285996A3 (en) * 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
DK3800189T3 (da) 2016-05-18 2023-07-31 Loxo Oncology Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) * 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CN111566102B (zh) 2017-10-18 2023-09-08 缆图药品公司 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
CN108191874B (zh) * 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
PT3773589T (pt) 2018-04-03 2024-02-06 Blueprint Medicines Corp Inibidor de ret para utilização no tratamento de cancro com alteração de ret
US11459334B2 (en) * 2018-04-16 2022-10-04 Shenzhen Targetrx, Inc. Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
WO2019165566A1 (es) 2018-06-22 2019-09-06 Comercializadora Innvento S.A. Artículo filtrante-absorbente multicapa que comprende una primera capa de un soporte poroso de carbón activado dispuesto sobre un fieltro no tejido de fibras de poliéster, una segunda capa de una película de polímero y una tercera capa de un agente activo; proceso para obtener dicho artículo; y uso del mismo
CA3224945C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
CN109232583A (zh) * 2018-11-29 2019-01-18 尚科生物医药（上海）有限公司 一种6-溴-3H-吡咯并[2,1-f][1,2,4]三嗪-4-酮的制备方法
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
CN111410648B (zh) * 2019-01-07 2024-03-29 浙江海正药业股份有限公司 一种手性c-KIT抑制剂药物关键中间体及其制备方法
PT3953357T (pt) * 2019-04-12 2024-07-24 Blueprint Medicines Corp Composições e métodos para tratar doenças mediadas por kit e pdgfra
EP3972977A1 (en) 2019-05-21 2022-03-30 Janssen Pharmaceutica NV Processes and intermediates for preparing a btk inhibitor
EP3997090A1 (en) 2019-07-09 2022-05-18 Sandoz AG Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor
CN114746096A (zh) * 2019-10-04 2022-07-12 缆图药品公司 使用阿伐替尼治疗嗜酸性粒细胞紊乱
GB201915447D0 (en) 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs
US20220370465A1 (en) * 2019-11-04 2022-11-24 Blueprint Medicines Corporation Treatment of mast cell diseases and eosinophilic disorders
WO2021113492A1 (en) 2019-12-06 2021-06-10 Schrödinger, Inc. Cyclic compounds and methods of using same
CN110950872A (zh) * 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) * 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
BR112022012684A2 (pt) 2019-12-27 2023-03-07 Schroedinger Inc Compostos cíclicos e métodos de uso dos mesmos
EP4118084A1 (en) 2020-03-11 2023-01-18 Teva Czech Industries s.r.o. Solid state forms of avapritinib and process for preparation thereof
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
WO2021257522A1 (en) * 2020-06-17 2021-12-23 Teva Czech Industries S.R.O Solid state forms of avapritinib salts
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
US20230365584A1 (en) 2020-09-10 2023-11-16 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
WO2022081626A1 (en) 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
EP4229060A1 (en) 2020-10-14 2023-08-23 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
CN112552339A (zh) * 2020-12-10 2021-03-26 安徽昊帆生物有限公司 一种o-二苯基磷酰羟胺的制备方法
US20240148732A1 (en) 2021-01-26 2024-05-09 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
CN113686987B (zh) * 2021-08-19 2022-04-26 海南医学院 一种用于检测Avapritinib中间体中对映异构体的方法
JP2024540411A (ja) 2021-11-08 2024-10-31 プロジェントス・セラピューティクス・インコーポレイテッド 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用
WO2023205226A1 (en) 2022-04-19 2023-10-26 Blueprint Medicines Corporation Kit inhibitors
US20240382493A1 (en) * 2023-05-18 2024-11-21 Blueprint Medicines Corporation Methods for treating systemic mastocytosis and gastrointestinal stromal tumors
WO2024249855A1 (en) * 2023-06-02 2024-12-05 Idrx, Inc. Combination therapy comprising kit inhibitors for use in the treatment of cancer
WO2025059027A1 (en) 2023-09-11 2025-03-20 Schrödinger, Inc. Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
WO2025170989A1 (en) 2024-02-05 2025-08-14 Blueprint Medicines Corporation High-risk disease features of indolent systemic mastocytosis and methods for treating

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
NZ516292A (en) * 1999-05-21 2004-01-30 Bristol Myers Squibb Co Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
US6784603B2 (en) * 2001-07-20 2004-08-31 Teledyne Lighting And Display Products, Inc. Fluorescent lighting apparatus
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
CA2483164C (en) 2002-04-23 2011-06-07 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2004076450A1 (en) * 2003-02-27 2004-09-10 J. Uriach Y Compañia S.A. Pyrazolopyridine derivates
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2005115397A2 (en) * 2004-04-29 2005-12-08 Pharmix Corporation Compositions and treatments for modulating kinase and/or hmg-coa reductase
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7348325B2 (en) * 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
BRPI0707312B1 (pt) 2006-01-27 2022-06-07 Shanghai Hengrui Pharmacetical Co., Ltd Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
EP2041138B1 (en) * 2006-07-07 2014-06-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR20100038108A (ko) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
KR20100003912A (ko) 2008-07-02 2010-01-12 삼성전자주식회사 동일 포맷의 미디어 파일 간에 미디어 정보 호환이 가능한미디어 파일을 생성하는 방법 및 장치와 미디어 파일을실행하는 방법 및 장치
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CN102573486A (zh) 2009-06-08 2012-07-11 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
CA2987503C (en) 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EP2536689A1 (en) 2010-02-17 2012-12-26 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
CA2822017C (en) * 2010-12-23 2015-04-07 Pfizer Inc. Glucagon receptor modulators
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
WO2014039714A2 (en) 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2895239C (en) 2012-12-21 2020-10-27 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112016008541B1 (pt) 2013-10-17 2022-11-22 Blueprint Medicines Corporation Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
KR20180048635A (ko) 2015-07-24 2018-05-10 블루프린트 메디신즈 코포레이션 Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
CA3005741A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
EP4285996A3 (en) 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
EP3856341B1 (en) 2019-04-12 2023-09-06 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019048878A (ja) * 2013-10-17 2019-03-28 ブループリント メディシンズ コーポレイション Ｋｉｔに関連する疾患を治療するために有用な組成物
US10807985B2 (en) 2013-10-17 2020-10-20 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US11827642B2 (en) 2013-10-17 2023-11-28 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
US11964980B2 (en) 2019-04-12 2024-04-23 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
US11999744B2 (en) 2019-04-12 2024-06-04 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
US12060354B2 (en) 2019-04-12 2024-08-13 Blueprint Medicines Corporation Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
US12252494B2 (en) 2019-04-12 2025-03-18 Blueprint Medicines Corporation Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis

Also Published As

Publication number Publication date
SI3057969T1 (sl) 2018-10-30
PL3409674T3 (pl) 2022-09-26
CA2926999A1 (en) 2015-04-23
PL3057969T3 (pl) 2018-11-30
KR102378689B1 (ko) 2022-03-24
HUS2100006I1 (hu) 2021-03-29
AU2014337314B2 (en) 2018-12-13
CA2926999C (en) 2021-10-19
WO2015057873A1 (en) 2015-04-23
NO2021012I1 (no) 2021-03-18
EP3057969B1 (en) 2018-06-13
US9944651B2 (en) 2018-04-17
PT3409674T (pt) 2022-07-18
US9200002B2 (en) 2015-12-01
RU2016118768A3 (OSRAM) 2018-06-21
TWI683814B (zh) 2020-02-01
RU2016118768A (ru) 2017-11-22
CN110003217B (zh) 2022-10-18
SMT201800448T1 (it) 2018-09-13
LTC3057969I2 (lt) 2022-09-26
EP3057969A1 (en) 2016-08-24
US9994575B2 (en) 2018-06-12
IL244677A0 (en) 2016-04-21
ES2683127T3 (es) 2018-09-25
BR112016008541B1 (pt) 2022-11-22
NZ718075A (en) 2021-10-29
ES2923888T3 (es) 2022-10-03
HUE039687T2 (hu) 2019-01-28
CY2021007I2 (el) 2021-06-25
DK3057969T3 (en) 2018-09-24
US20210284645A1 (en) 2021-09-16
MX2016004927A (es) 2016-07-11
SG11201602937UA (en) 2016-05-30
BR112016008541A2 (pt) 2017-09-12
RU2706235C2 (ru) 2019-11-15
JP2016538257A (ja) 2016-12-08
US10807985B2 (en) 2020-10-20
LTPA2021003I1 (lt) 2021-04-12
EP3409674A1 (en) 2018-12-05
CN110003217A (zh) 2019-07-12
US20150111887A1 (en) 2015-04-23
US11827642B2 (en) 2023-11-28
JP6782756B2 (ja) 2020-11-11
CY2021007I1 (el) 2021-06-25
CN105658652A (zh) 2016-06-08
RS57542B1 (sr) 2018-10-31
MX365614B (es) 2019-06-07
KR20160062173A (ko) 2016-06-01
ZA201601970B (en) 2019-06-26
PH12016500611A1 (en) 2016-06-13
US20190144454A1 (en) 2019-05-16
US20170204104A1 (en) 2017-07-20
HK1221461A1 (zh) 2017-06-02
CY1121182T1 (el) 2020-05-29
US20230129944A1 (en) 2023-04-27
AU2014337314A1 (en) 2016-04-07
EP3409674B1 (en) 2022-04-06
IL244677B (en) 2019-10-31
NL301094I2 (nl) 2021-03-18
TW201546062A (zh) 2015-12-16
HUE059041T2 (hu) 2022-10-28
JP2019048878A (ja) 2019-03-28
UY35787A (es) 2015-04-30
PT3057969T (pt) 2018-07-11
US20160102097A1 (en) 2016-04-14
CN105658652B (zh) 2019-04-12
US20240317757A1 (en) 2024-09-26
LT3057969T (lt) 2018-07-10
HRP20181388T1 (hr) 2018-10-19

Similar Documents

Publication Publication Date Title
JP6446040B2 (ja) Ｋｉｔに関連する疾患を治療するために有用な組成物
US9884861B2 (en) Compositions useful for treating disorders related to kit
JP2018521076A (ja) Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物
HK40001809A (en) Compositions useful for treating disorders related to kit
HK40008504A (en) Compositions useful for treating disorders related to kit
HK40008504B (en) Compositions useful for treating disorders related to kit
HK1221461B (zh) 可用於治疗与kit相关的病症的组合物
KR20150049285A (ko) Ｒｏｓ 카이네이즈 저해활성을 갖는 2,4,6-삼치환된 피리미딘 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181130

R150 Certificate of patent or registration of utility model

Ref document number: 6446040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250